摘要
目的探讨乌司他丁治疗慢性阻塞性肺疾病急性加重期(AECOPD)患者合并全身炎症反应综合征(SIRS)的临床疗效。方法选取该院于2015年4月—2016年10月收治的患者80例,随机分为观察组和对照组各40例,两组患者均给予常规治疗,对照组加用血必净,观察组加用乌司他丁,观察治疗前后血清肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、白细胞介素-1β(IL-1β)和C反应蛋白(CRP)水平的变化,临床症状改善情况。结果两组患者经治疗后显示,观察组血清TNF-α、IL-6、IL-1β、CRP水平,以及临床症状评分,肺功能指标分别为(246.7±27.0)ng/L、(10.4±3.1)ng/L、(17.6±3.0)ng/L、(14.0±4.2)mg/L,(3.6±1.4)分,改善幅度优于对照组,差异有统计学意义(P<0.05)。结论乌司他丁能快速缓解AECOPD合并SIRS患者的临床症状,改善肺功能,减轻机体炎症反应。
Objective This paper tries to investigate the clinical efficacy of ulinastatinin treatment of acute exacerbation of chronic obstructive pulmonary disease(AECOPD)complicated by systemic inflammatory reaction syndrome(SIRS).Methods A total of 80 eligible patients from April 2015 to October 2016 were selected and randomly divided into the observation group and the control group,with 40 patients in each group.Both groups were given conventional therapies;the control group was given Xuebijing(TCM)additionally,while the observation group was given ulinastatin additionally;the changes in serum levels of tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),interleukin-1β(IL-1β),and C reactive protein(CRP),clinical symptom improving conditions before and after treatment were observed.Results After treatment,the observation group of serum TNF-α,IL-6,IL-1β,CRP level and clinical symptom score,lung function index were(246.7±27.0)ng/L,(10.4±3.1)ng/L,(17.6±3.0)ng/L,(14±4.2)mg/L,(3.6±1.4)points,significantly better than the control group,the difference was statistically significant(P<0.05).Conclusion Ulinastatin can rapidly relieve the clinical symptoms,improve the lung function,and lighten the inflammatory reactions in patients with AECOPD complicated by SIRS.
作者
陈杰
陈霞
CHEN Jie;CHEN Xia(Department of Respiratory Medicine,the People’s Hospital of Jianyang,Jianyang,Sichuan Province,641400 China;West China Hospital,Sichuan University,Chengdu,Sichuan Province,610041 China)
出处
《系统医学》
2017年第20期40-41,47,共3页
Systems Medicine
